Toward standardization in bladder cancer clinical trials: Guidance from the SITC-IBCG expert panel.

"Competing interests: AAM: Nothing to disclose. AMK: Consulting fees: Abbott Molecular, Arquer, ArTara, Asieris, Astra Zeneca, BioClin Therapeutics, Biological Dynamics, BMS, Cepheid, Cold Genesys, Eisai, Engene, Ferring, FerGene, Imagin, Incyte DSMB, Janssen, MDxHealth, Medac, Merck, Pfizer, Photocure, ProTara, Roviant, Seattle Genetics, Sessen Bio, Theralase, TMC Innovation, US Biotest, Urogen; Contracted research: Adolor, BMS, Fergene, FKD Industries, Heat Biologics, Merck, Photocure, SWOG/NIH; Patent: CyPRIT (Cytokine Predictors of Response to Intravesical Therapy) Joint with UT MD Anderson Cancer Center. AK: Nothing to disclose. MDG: Consulting fees: Inovio, NuMab, Janssen, Merck, Glaxo Smith Kline, Genentech, Bristol-Myers Squibb, Seattle Genetics, Dracen, Dragonfly, Astellas, Novartis, Pfizer, Astra Zeneca, Incyte, Dendreon, Lilly, EMD Serono, Aileron Therapeutics; Ownership interest: RAPPTA Therapeutics."

"Funding: The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors."